Pembrolizumab Improves Survival, Tumor Control in Advanced Merkel Cell Carcinoma

Pembrolizumab (Keytruda), an immunotherapy, showed durable tumor control and overall survival as a first-line treatment for advanced Merkel cell carcinoma (MCC), an aggressive skin cancer, according to new data from a phase 2 trial.
 
Although MCC is rare, incidence has increased by 95% between 2000 and 2013. The 5-year survival rate for advanced disease ranges between 14% and 27%.
 
The study, which was published in the Journal of Clinical Oncology, included 50 adults naïve to systemic therapy for advanced MCC who received pembrolizumab (2 mg/kg every 3 weeks) for up to 2 years. Among the 50 patients, 64% had Merkel cell polyomavirus-positive tumors. In total, 56% of patients responded to the treatment, 24% had a complete response, and 32% had a partial response. The overall response rate in virus-positive tumors was 59% and 53% in virus-negative tumors, according to the data. The average length of progression-free survival was 26.8 months, with a 24-month rate of 48.3%, and a 24-month overall survival rate of 68.7%.
 
“This study shows the amazing ability of our immune system to fight off and destroy an aggressive form of skin cancer called Merkel cell carcinoma,” lead study author Adam Riker, MD, FACS, professor and chief of surgical oncology, said in a statement. “The study drug, pembrolizumab, which is a new form of immunotherapy, blocks a specific receptor in our bodies, resulting in a super charging of our immune system to both recognize and destroy cancer cells. The overall impressive results show that this form of immunotherapy is quite effective, giving us an important treatment option for patients with Merkel cell carcinoma that has spread within the body.”
 
According to the study, nearly all of the patients experienced some type of treatment-related adverse effect and 7 patients discontinued the trial. Additionally, 1 death occurred in a 73-year old patient with widely metastatic MCC and pre-existing atrial fibrillation who withdrew from the trial and died 10 days after a single infusion of pembrolizumab.
 
The findings present the longest observation to date of patients with advanced MCC receiving first-line anti-programmed cell death-1 therapy, the authors wrote in the study. Compared with historical data from patients treated with first-line chemotherapy, pembrolizumab demonstrated durable tumor control, a generally tolerable safety profile, and a favorable overall survival, they concluded.
 
References
 
Nghiem P, Bhatia S, Lipson EJ, et al. Durable tumor regression and overall survival in patients with advanced merkel cell carcinoma receiving pembrolizumab as first-line therapy.  2019. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.18.01896
 
Immunotherapy Drug Used As 1st-Line Therapy for Merkel Cell Carcinoma Improved Survival [news release]. LSU Health. https://www.lsuhsc.edu/newsroom/Immunotherapy%20Drug%20Used%20As%201st-Line%20Therapy%20for%20Merkel%20Cell%20Carcinoma%20Improved%20Survival.html. Accessed February 7, 2019.
 
 
 



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Top news of the day across the health care landscape.
Pembrolizumab (Keytruda, Merck) is the first anti-PD-1 therapy approved in the adjuvant setting across patients with stage 3 melanoma.
The sBLA is based on data showing significant improvement in overall survival and progression-free survival in patients with advanced renal cell carcinoma.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$